Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization

Journal of Pharmacological Sciences

Volumn 107, Issue 1, 2008, Pages 66-79

  Hishinuma, Shigeru ^a   Sato, Yuko ^a   Kobayashi, Yusuke ^a   Komazaki, Hiroshi ^a   Saito, Masaki ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Histamine H1 receptor; Intact cell binding; Membrane permeability; Receptor internalization; Sedative and non sedative antihistamines

Indexed keywords

AZELASTINE; BETOTASTINE; CAREBASTINE; CHLORPHENIRAMINE MALEATE; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; EPINASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN FUMARATE; MEPYRAMINE MALEATE; MEQUITAZINE; OLOPATADINE; OXATOMIDE; PIRDONIUM; PROMETHAZINE; TERFENADINE;

ARTICLE; CELL ASSAY; CELL MEMBRANE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY;

EID: 44349188062     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071865     Document Type: Article

References (35)

1. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure regulation, and clinical implications. Neurobiol Dis. 2004:16:1-13.
2. Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;33:1305-1324.
3. 1 receptors. Life Sci. 1981;29:547-552.
4. 3H]mepyramine from peripheral vs. ventral nervous system receptors by loratadine, a non-selective antihistamine. Eur J Pharmacol. 1986;12:153-155.
5. 1 receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol. 1993;232:199-205.
6. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target. 2001;9:223-228.
7. 1-antagonists. Drug Metab Dispos. 2003;31:312-318.
8. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25:423-429.
9. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, et al. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology. 2004;72:92-98.
10. 1-antihistaminic agents in relation to their central side-effects. Eur J Pharm Sci. 1994;2:373-384.
11. 1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical anti-histamine. Br J Clin Pharmacol. 2001;52:501-509.
12. Sterne-Marr R, Benovic JL. Regulation of G protein-coupled receptors by receptor kinases and arrestins. Vit Horm. 1995;51:193-234.
13. Ferguson SS, Downey WE III, Colapietro A-M, Barak LS, Menard L, Caron MG. Role of β arrestin in mediating agonist promoted G protein-coupled receptor sequestration. Science. 1996;271:363-366.
14. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res.1996;51:319-353.
15. 2-adrenergic receptor. Nature. 1996;383:447-450.
16. 2-adrenergic receptor facilitate sequestration. Biochemistry. 1996;35:4155-4160.
17. 1-receptor sequestration. Br J Pharmacol. 1995;116:2715-2723.
18. 1 receptors in human U373 MG astrocytoma cells. J Neurochem. 1998;71:2626-2633.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
20. Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos. 2006;34:793-799.
21. Takahashi H, Ishida-Yamamoto A, Lizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol. 2004;29:526-532.
22. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, et al. Properties of olopatadine hydrochloride, a new antiallergic /antihistaminic drug. Arzneimittelforschung. 2004;54:809-829.
23. 1-antihistaminic properties. Chemistry of epinastine. Arzneimittelforschung. 1990;40:440-446.
24. 1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004;32:519-524.
25. 1-receptor antagonist.] Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 1994;103:121-135. (text in Japanese with English abstract)
26. 1-antagonist ebastine and its metabolite carebastine. J Drug Target. 2000;8:383-393.
27. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001;10:547-560.
28. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;10:751-762.
29. Wang EJ, Casciano CN, Clement RP, Johnson WW. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001;29:1080-1083.
30. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004;18:399-411.
31. Heuser JE, Anderson RGW. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J Cell Biol. 1989;108:389-400.
32. Martin U, Romer D. The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittelforschung. 1978;28:770-782.
33. Tasaka K, Akagi M. Anti-allergic properties of a new histamine antagonist, 4-(p-chlorobenzyl)-2-[N-methyl-perhydroazepinyl-(4)]-1-(2H)- phthalazinone hydrochloride (azelastine). Arzneimittelforschung. 1979;29:488-493.
34. Awouters F, Niemegeers CJ, Van den Berk J, Van Neuten JM, Lenaerts FM, Borgers M, et al. Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators. Experientia. 1977;33:1657-1659.
35. 1-receptor in CHO-K1 cells. Br J Pharmacol. 2005;146:612-624.